Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00628
|
|||||
| Drug Name |
Captopril
|
|||||
| Synonyms |
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline; Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Apopril (TN); Asisten; C 4042; Capoten; Capoten (TN); Captolane; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; Captoprilum; Captoprilum [INN-Latin]; Captopryl; Captoril; Captril; Cesplon; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; D-3-Mercapto-2-methylpropionylproline; Dilabar; Garranil; Garranil (discontinued); Hipertil; Hypertil; Isopresol; L-Captopril; Lopirin; Lopirin [Switzerland]; Lopril; MCO; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; SA 333; SQ 14,225; SQ 14225; SQ-14,225; SQ-14,534; SQ-14225; SQ-14534; Tenosbon; Tensiomin; Tensobon; Tensoprel; X8Z; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11:BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H15NO3S
|
|||||
| Canonical SMILES |
CC(CS)C(=O)N1CCCC1C(=O)O
|
|||||
| InChI |
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
|
|||||
| InChIKey |
FAKRSMQSSFJEIM-RQJHMYQMSA-N
|
|||||
| CAS Number |
CAS 62571-86-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 217.29 | Topological Polar Surface Area | 58.6 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321204
,11110941
,11335383
,11360622
,11363582
,11366144
,11368706
,11372295
,11374460
,11376868
,11461594
,11484758
,11489027
,11491203
,11492626
,11494502
,11533495
,12013747
,14797867
,15195876
,17404865
,22391411
,24278149
,24893111
,26612024
,26679590
,26747043
,26747044
,26751563
,26758381
,3154070
,34709396
,46392259
,46487953
,46506879
,47365058
,47440133
,47515193
,47515194
,47515195
,47736347
,47736348
,47959603
,49698307
,7847317
,7978852
,8149632
,8178487
,823180
,855925
|
|||||
| ChEBI ID |
ChEBI:3380
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Captopril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.